Edwards Lifesciences [EW]
Task 6 · investment-memo v1.6.0 · built 2026-07-28, migrated 2026-07-29 · spot $83.675
Catalyst Criteria is MEASURED: dated events that would confirm or refute the Valuation Criteria implied path (21.1% required vs 10.8% demonstrated). No position verdict is stated or implied by this calendar.
Every entry carries an explicit upgrade/downgrade threshold. Entries marked [UNPUBLISHED] resolve from free public corpora without waiting for an earnings call — those are the ones that generate lead time.
The most consequential scheduled event for this franchise in a decade. Opened at Edwards' own request following FDA's 2025-04-30 label expansion to asymptomatic severe AS. Proposed memo posted 2026-06-15; comments closed 2026-07-15.
Watch four specific items in the final memo:
| Item | Proposed | If retained → | If dropped → |
|---|---|---|---|
| Hospital procedure-volume floors | Eliminated | DOWNGRADE — the centre-expansion vector is dead | Bear weight 25% → 20% |
| Dual-operator requirement | One operator may perform routine TAVR | DOWNGRADE — the surgeon bottleneck persists | Largest single unlock; bear weight → 18% |
| Symptomatic severe AS | CED removed, ordinary coverage | Neutral | Mild positive, administrative |
| Asymptomatic severe AS | Covered, under CED with active comparator | Expected. If coverage is denied → DOWNGRADE hard | If granted without an active-comparator requirement → UPGRADE, materially faster ramp |
Thresholds. Finalised substantially as proposed → trigger T2 partially fires; conversion price rises from $71.50 toward ~$80. Volume floors and the dual-operator rule both retained → Quality Criteria's mechanism is substantially dead; move toward Avoid and re-underwrite.
Source to check: cms.gov/medicare-coverage-database, NCA tracking sheet ID 321. Cadence: weekly from
2026-08-25.
| Date | Event | Importance | Upgrade threshold | Downgrade threshold |
|---|---|---|---|---|
| 2026-09-13 | CMS final NCD decision memo (CAG-00430R2) | HIGH | Volume floors removed AND single-operator permitted | Either requirement retained |
| ~2026-10-22 | Q3-2026 results (Q3-25 was 2025-10-30; Q3-24 2024-10-24) | HIGH | TAVR growth >11% with the ACURATE comparison lapped → fires T4 leg 1 | TAVR growth <7% → the reacceleration was the competitor exit |
| ~late Oct 2026 | TCT 2026: PROGRESS (moderate AS, NCT04889872, n=2,250) — company-confirmed | HIGH | Positive on the primary effectiveness endpoint → opens the moderate-AS pool, a step-change in TAM | Negative or equivocal → the disease-stage expansion runway is capped, not delayed. Move to Avoid |
| ~late Oct 2026 | TCT 2026: CLASP IITR (PASCAL tricuspid) — company-confirmed | MEDIUM | Supports the Q4 PASCAL tricuspid approval | A miss delays the Q4 approval |
| 2026-11-01 | ALT-FLOW II primary completion (APTURE shunt, NCT05686317, n=100, heart failure) [UNPUBLISHED] | MEDIUM | Positive → the heart-failure vector becomes sizeable rather than a $2.7m line | Termination → close the vector |
| Q4-2026 | PASCAL tricuspid US indication approval — company-guided | MEDIUM | Approved on time → TMTT FY2027 guide above $1.05bn becomes reachable | Slip into 2027 → trim TMTT growth 3-4pp |
| Q4-2026 | Next-generation PASCAL with Capture Clarity, US and Europe — company-guided | MEDIUM | Both geographies on time | Either slips |
| Q4-2026 | ECLIPTIS surgical LAA "measured rollout" | LOW | First disclosed revenue contribution | Silent → treat as immaterial |
| ~2026-12 | Bi-monthly FINRA short-interest prints | LOW | Immaterial at 1.98% of float unless it triples | — |
| ~2027-01 | ALLIANCE Mitral (NCT06167213) actually starts — SAPIEN X4 into the mitral position [UNPUBLISHED] | HIGH for the variant | Starts on schedule → the strongest available the dissolved duration-variant test (old Gate 2B) unlock. Fires T3 if management also names it | Slips or is withdrawn → the X4 mitral extension is not real |
| ~2027-02 | FY2026 results and FY2027 guidance | HIGH | FY2027 revenue guide >$7.7bn (vs model $7,491m) or TMTT >$1.05bn | FY2027 cc growth guided below 8% → bear weight to 35%, close to the flip point |
| ~2027-04 | Q1-2027 results | MEDIUM | Second consecutive post-lap TAVR print >10% | TAVR <7% |
| 2027-07 | ALLIANCE primary completion (NCT05172960, n=1,234) — SAPIEN X4 pivotal [UNPUBLISHED] | HIGH for the variant | Any disclosure of X4 timing, ASP or placement plan → re-underwrite the dissolved duration-variant test (old Gate 2B) immediately | Push-out beyond 2028 |
| 2027-12-30 | TTVR STRONG CED primary completion (NCT06833476, n=2,044) [UNPUBLISHED] | MEDIUM | Supports permanent national coverage for TTVR | — |
| 2029-06 | PROGRESS full primary completion | LOW | Long-dated. Note the discrepancy: management guides a TCT-2026 presentation while the registry lists a 2029-06 primary completion — the October readout is therefore an interim or cohort analysis, not the full primary endpoint. Read it as such. | — |
Handed to equity-research:catalyst-calendar and equity-research:thesis-tracker for ongoing maintenance.
| ID | Item | Baseline 2026-07-28 | Cadence | Trigger |
|---|---|---|---|---|
| E-U1 | CMS docket CAG-00430R2 | Proposed memo 2026-06-15; final due 2026-09-13 | weekly to Sept | Any posting |
| E-U2 | Management mention of SAPIEN X4 | ZERO in 19 quarters of 8-K Ex-99.1 | quarterly | Any mention → immediate the dissolved duration-variant test (old Gate 2B) re-underwrite |
| E-U3 | ALLIANCE (NCT05172960) | Recruiting, n=1,234, PC 2027-07 | monthly | Status or date change |
| E-U4 | ALLIANCE Mitral (NCT06167213) | Not yet recruiting, start 2027-01 | monthly | Start, slip, or withdrawal |
| E-U5 | EW trial-start cohort | 17 (2021) → 6 (2025) → 7 (2026) | semi-annual | 2027 starts < 6 → downgrade the innovation runway |
| E-U6 | PubMed "transcatheter tricuspid valve replacement" | 62 (2024) → 146 (2025) → 126 (2026 partial) | semi-annual | Full-2026 < 146 → TMTT deceleration is real |
| E-U7 | PubMed "asymptomatic severe aortic stenosis" | 18 (2024) → 52 (2025) → 33 (2026 partial) | semi-annual | Full-2026 < 40 → the guideline effect is fading |
| E-U8 | ALT-FLOW II (NCT05686317) | Active, PC 2026-11-01 | monthly | Completion or termination |
| E-U9 | openFDA PMA originals for EW | Latest: SAPIEN M3 P250019, 2025-12-22 | monthly | Any new original PMA |
| E-U10 | IHFM revenue line | $2.7m in Q2-2026 | quarterly | >$25m in any quarter → re-scope the heart-failure vector |
| E-U11 | Price alert | Spot $83.68 | daily | $71.50 → T1 fires, conversion review; $58.00 → invalidation review |
| E-U12 | CFO transition | Ullem → Mistras in progress | quarterly | Formal 8-K Item 5.02; watch for guidance-philosophy changes at the first Mistras-led call |
2026-09-14 — the trading day after the CMS final decision memo is due. Whatever CMS publishes moves either the bear weight or the Quality Criteria mechanism, and both feed straight into the flip point.
Second review: ~2026-10-22, Q3-2026 results plus the TCT PROGRESS readout, which together resolve the single largest unresolved uncertainty in the memo — how much of the TAVR reacceleration was the Boston Scientific ACURATE exit.